X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ADCOCK INGRAM (S. Africa) - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   ADCOCK INGRAM
EQUITY SHARE DATA
    NOVARTIS
Mar-16
ADCOCK INGRAM
Jun-14
NOVARTIS/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs982377-   
Low Rs556272-   
Sales per share (Unadj.) Rs252.9112.1-  
Earnings per share (Unadj.) Rs62.1-28.3-  
Cash flow per share (Unadj.) Rs63.3-23.4-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs363.688.0-  
Shares outstanding (eoy) m31.96168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.02.9 105.1%   
Avg P/E ratio x12.4-11.5 -107.8%  
P/CF ratio (eoy) x12.2-13.9 -87.7%  
Price / Book Value ratio x2.13.7 57.4%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m24,58054,766 44.9%   
No. of employees `0000.84.3 17.5%   
Total wages/salary Rs m1,8013,437 52.4%   
Avg. sales/employee Rs Th10,748.94,409.0 243.8%   
Avg. wages/employee Rs Th2,395.2800.7 299.2%   
Avg. net profit/employee Rs Th2,641.1-1,111.0 -237.7%   
INCOME DATA
Net Sales Rs m8,08318,928 42.7%  
Other income Rs m829133 625.7%   
Total revenues Rs m8,91319,061 46.8%   
Gross profit Rs m234-3,280 -7.1%  
Depreciation Rs m37817 4.5%   
Interest Rs m2513 0.4%   
Profit before tax Rs m1,025-4,477 -22.9%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m752280 268.8%   
Profit after tax Rs m1,986-4,769 -41.6%  
Gross profit margin %2.9-17.3 -16.7%  
Effective tax rate %73.4-6.2 -1,174.0%   
Net profit margin %24.6-25.2 -97.5%  
BALANCE SHEET DATA
Current assets Rs m12,67813,863 91.4%   
Current liabilities Rs m2,4337,800 31.2%   
Net working cap to sales %126.732.0 395.7%  
Current ratio x5.21.8 293.2%  
Inventory Days Days33111 29.5%  
Debtors Days Days22124 18.1%  
Net fixed assets Rs m698,081 0.9%   
Share capital Rs m16088 181.8%   
"Free" reserves Rs m11,4600-   
Net worth Rs m11,62114,856 78.2%   
Long term debt Rs m05,221 0.0%   
Total assets Rs m14,40028,065 51.3%  
Interest coverage x570.5-7.7 -7,378.2%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.7 83.2%   
Return on assets %13.8-15.2 -91.0%  
Return on equity %17.1-32.1 -53.2%  
Return on capital %23.6-19.8 -119.0%  
Exports to sales %0.70-   
Imports to sales %18.60-   
Net fx Rs m-1,6350-   
CASH FLOW
From Operations Rs m2,5311,616 156.6%  
From Investments Rs m-8,270-496 1,667.0%  
From Financial Activity Rs m-3864,738 -8.1%  
Net Cashflow Rs m-6,1255,858 -104.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.2 Rs / ZAR

Compare NOVARTIS With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: ELDER PHARMA  ALEMBIC PHARMA  VENUS REMEDIES  CIPLA  GSK PHARMA  



Today's Market

Of Rising Stock Markets, Reduction in Government's Additional Borrowing, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a strong note yesterday. At the closing bell yesterday, the BSE Sensex crossed its 35,000 mark for the first time and stood higher by 311 points (up 0.9%).

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 17, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS